Sequenom Q2 Revenues Fall 11 Percent on Lower Reimbursement Rates for NIPT

Aug 08, 2016

This article has been updated to clarify the reasons for the year-over-year decline in diagnostic services revenue.

NEW YORK (GenomeWeb) – Sequenom's second quarter 2016 revenues fell 11 percent compared to the second quarter of 2015, the firm reported in a filing with the US Securities Exchange Commission.

The molecular diagnostics company reported $29.3 million in Q2 2016 revenues, down from $32.8 million in Q2 2015, missing analysts' average estimate of $30.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Main menu